ICAD earnings

NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligenceFollowing the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutionsRadNet will host a conference call and

NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenues increased 14% to $5.4 millionGross Profit Margin of 86%382 Total deals closed in 2024, 42 of which were ProFound CloudProFound Detection V4.0 granted FDA clearanceExpanded global reach with ne

NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064 About iCAD, Inc. iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered

NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024.  Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3 million, up 10% year over yearTotal revenues were $4.2 million, up 4% year over yearGross Profit Margin was 86%, consistent with prior year13 cloud deals closed during the quarter, key wins include: University California San Diego (UCSD) signed a 3-year Cloud deal Charlot

NASHUA, N.H., Nov. 05, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024. Earnings call details are as follows: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 509249Webcast: https://www.webcaster4.com/Webcast/Page/2879/51509 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutio

NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024.  Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7%Total revenues were $5.0 million, up 21%Gross Profit Margin was 84%, up from 81%GAAP Net loss from continuing operations ($1.7) million, improvement from ($2.3 million) "The second quarter of 2024 was highlighted by strong revenue growth of 21%, which demonstrat

NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 227167Webcast: https://www.webcaster4.com/Webcast/Page/2879/50989 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that ena

NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10%Total revenues were $5.0 million, up 14%Gross Profit Margin % was 83%, up from 82%GAAP Net Loss from continuing operations ($1.2) million, improvement from ($3.1) millionOperating cash flow was ($1.2) million, improvement from ($1.5) million "Over the past year, we have demonstrated strong

NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Page/2879/50453 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medica

NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Page/2879/50453 About iCAD, Inc.iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medic

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-yearFull-Year Operating Cash Flow ($5) million vs. ($12.8) million prior yearYear ending cash balance of $21.7M NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended December 31, 2023, as compared to the corresponding period of the last fiscal year. Fourth Quarter 2023 Financial Highlights: Total ARR was $8.7 million, up 15%Total revenues were $4.7 million, up

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024. Earnings call details are as follows:Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 402294Webcast: https://www.webcaster4.com/Webcast/Page/2879/49733 About iCADiCAD, Inc. (NASDAQ:ICAD) is a global leader on a miss

NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023. Highlights: Completed sale of Xoft, its therapy business line, to Elekta thereby enabling the Company to focus exclusively on its core business of AI-powered breast health solutions.Company re-introduces Annual Recurring Revenue (ARR) metrics to highlight progress of subscription sales and growing recurring revenue model.Company does not need to raise additional funding to pu

NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that it will release financial results for the third quarter ended September 30, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, November 13, 2023. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 381129Webcast: https://www.webcaster4.com/Webcast/Page/2879/49364 About iCADiCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a wor

NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023. Highlights: iCAD signs 20-year worldwide development and commercialization agreement with Google Health to integrate Google's AI technology with its ProFound Detection for 2D Mammography for use upon regulatory approval as an independent reader for breast cancer screening.iCAD signs strategic multi-year commercial agreement with Radiology Partners, the nation's largest radiology practice providing 15% of all U.S. mammogra

NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023. Earnings call details are as follows: Domestic: 888-506-0062International: 973-528-0011Participant Access Code: 460678Webcast: https://www.webcaster4.com/Webcast/Page/2879/48562 About iCAD, Inc.Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com. F

NASHUA, N.H., May 15, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023.  Highlights:  ●Body of evidence supporting iCAD's technologies grows, with compelling new research supporting Company's Breast AI Suite and Xoft presented at key industry tradeshows and published in peer-reviewed journals ●Leadership team strengthened with seasoned executives poised to accelerate key initiatives in the Company's strategic expansion ●Company implemented a number of strategic changes, including continued cost reduc

NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, May 15, 2023. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 380859Webcast: https://www.webcaster4.com/Webcast/Page/2879/48223 About iCAD, Inc.Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions.

Strategy focused on profitability by end of 2024, using current cash on hand New leadership to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., March 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022. Highlights: Company continues to invest in Detection business, driving commercial growth through global adoption of Breast AI Suite while exploring strategic options for Therapy segmentSeveral strategic partnership agreements signed in Q4, including Google Health and Solis Ma

NASHUA, N.H., March 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2022, after the market close, and host a conference call at 4:30 PM ET on Tuesday, March 28, 2023. Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter ended December 31, 2022 to be approximately $6.5 million. The Company is implementing measures to align its cost base with changes in revenue from its ongoing transition from perpetual to subscription softwar

Company implements corporate strategic realignment Partnership-based recurring revenue model anticipated to drive future growth Cost structure reduction to decrease expenses by over $3 million annually Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., Nov. 10, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and nine months ended September 30, 2022. Highlights: Increased demand for flexible subscription model drives spike in subscription sales, with more subscriptions booked in the third quarte

NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on November 10, 2022. Conference CallThursday, November 10, 2022 at 4:30 PM ETDomestic: 888-506-0062International: 973-528-0011Conference ID: 393244Webcast: https://www.webcaster4.com/Webcast/Page/2879/46603    About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therap

Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., Aug. 10, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2022. Recent Highlights: Increased demand for subscription and SaaS-based models is accelerating customer acquisition and establishing predictab

NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022. August 10, 2022 at 4:30 PM ETDomestic: 888-506-0062                International: 973-528-0011                Conference ID: 718241        Webcast: https://www.webcaster4.com/Webcast/Page/2879/46166                 About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer

NASHUA, N.H., May 11, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022. Highlights: Commercial reorganization shows early success leading to a ProFound AI® enterprise agreement at a world-renowned academic research institution with multiple locations throughout the U.S.Profound AI® Risk clinical research progresses, with new data to be presented at both the International Workshop on Breast Imaging (IWBI) and the European Congress of Radiology (ECR) in Q2GLIOX trial examining use of Xoft® intraoperati

NASHUA, N.H., April 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11. Wednesday, May 11th at 4:30 PM ETDomestic:888-506-0062International: 973-528-0011Conference ID:728427Webcast: https://www.webcaster4.com/Webcast/Page/2879/45416 About iCAD, Inc. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information

Launched ProFound AI® Risk, the world's first clinical decision support tool for short term breast cancer risk estimation Demonstrated compelling survival data for the use of Xoft® Brain IORT in recurrent glioblastoma (GBM) as published in Surgical Neurology International Company to Host Conference Call & Webcast Today at 4:30 PM ET NASHUA, N.H., Feb. 28, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and 12 months ended December 31, 2021. Revenues for the three-month and 12-month periods ended December 31, 2021 were $7.8 m

NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, February 28. Monday, February 28th at 4:30 PM ET Domestic:877-407-0784International:201-689-8560Conference ID:13726987Webcast:https://themediaframe.com/mediaframe/webcast.html?webcastid=ELUrpENc About iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and ther

- Third Quarter Revenues of $9.4 Million Represented 20% Sequential Quarter Growth over the Second Quarter of 2021, Driven by 26% Growth in Detection Revenue and 10% Growth in Therapy Revenue - - Third Quarter 2021 Revenues Represented 31% Growth Compared to the Third Quarter 2020 - - Improving Enterprise Sales in the Third Quarter of 2021 Resulted in a 41% Sequential Quarter Increase in Detection Product Revenues - - Xoft® Product Revenue Reflected a 34% Sequential Quarter Increase in the Third Quarter of 2021 with Continued Surge in Dermatology Controller Installations - - Company to Host Conference Call & Webcast today at 4:30 PM ET - NASHUA, N

NASHUA, N.H., Oct. 26, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Tuesday, November 9. Tuesday, November 9th at 4:30pm ETDomestic:855-327-6837International:631-891-4304Conference ID:10016811Webcast:https://themediaframe.com/mediaframe/webcast.html?webcastid=cp8sjumj About iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions

NASHUA, N.H., Aug. 05, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2021. Revenues for the three-month and six-month periods ended June 30, 2021 were $7.8 million and $16.5 million, respectively, compared to $5.6 million and $12.1 million in the three and six month periods ended June 30, 2020, respectively. Net loss for the three-month and six-month periods ended June 30, 2021 were $3.3 million and $4.9 million, respectively, compared to $2.4 million and $14.2 million in the three and six mont

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5. Thursday, August 5th @ 4:30pm ETDomestic:888-254-3590International:323-994-2082Conference ID:6177004Webcast:    http://public.viavid.com/index.php?id=145901 About iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more in

Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue ProFound AI® Product Revenue Increased 21% in the Fourth Quarter of 2020 as Compared to 2019 Fourth Quarter Fueled by Launch of ProFound AI® Risk Assessment Offering Recent Agreement with Solis Mammography Represents Largest Single Contract in iCAD’s History and Includes Both ProFound AI® Detection and Risk Net Loss Declined 52% to $0.07 Per Share in the Fourth Quarter of 2020 as Compared to 2019 Fourth Quarter Conference Call Today at 4:30 p.m. ET NASHUA, N.H., Feb. 24, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader p